iShares Biotechnology ETF
iShares Trust · 1 share class
Fund classification
Classified from what the fund holds · as of 2026 Q2
iShares Biotechnology ETF is a U.S. equity index ETF that tracks the NYSE Biotechnology Index.
- Asset class
- Equity
- Region
- United States
- Management
- Index (passive)
- Fund type
- ETF
- Features
- Non-diversified
Fund profile
As filed in the prospectus · 2025 Q3
The iShares Biotechnology ETF (the Fund ) seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector.
The fund tracks the NYSE Biotechnology Index using representative sampling, holding a portfolio of U.S.-listed biotechnology and biotech-tools companies that collectively mirrors the index's characteristics; it invests at least 80% of assets in index components and may use derivatives and cash for up to 20%. Because the fund samples rather than holds all index securities, its returns may diverge from the index.
| Share class | Expense ratio |
|---|---|
| IBB | 0.44% |
Portfolio turnover 18.00% · as of 2025 Q3
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q2
| Stocks | 99.88% |
| Cash & short-term | 12.04% |
| Other | 0.01% |
| Derivatives | 0.00% |
These positions come to 111.92% of the fund's net assets. This counts only what the fund reported holding — the holdings disclosure covers assets, not liabilities such as borrowings — so it is not expected to reconcile to 100%.
Derivatives are shown at market value, not notional exposure.
Sector allocation
The same holdings as Allocation above, grouped by market sector instead of asset type · as of 2026 Q2
| Health Care | 80.7% |
| Cash | 10.8% |
| International | 8.5% |
| Industrials | 0.1% |
| 2 smaller | 0.0% |
Government, Securitized and Cash are non-corporate buckets; International is foreign holdings we don’t sector-classify, and Other is the residual (held funds, unresolved names).
Latest quarter
What changed since the fund's previous filing
New: Ascendis Pharma A/S, Arcellx, Inc.
Exited: Ascendis Pharma A/S, Arcellx, Inc., Terns Pharmaceuticals, Inc., Amicus Therapeutics, Inc., Apellis Pharmaceuticals, Inc., Centessa Pharmaceuticals plc, Day One Biopharmaceuticals, Inc., KalVista Pharmaceuticals, Inc.
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026
May 2026 and Jun 2026 have been filed since the trailing figures were struck, so they are not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Reported price | Value | Shares |
|---|---|---|---|---|---|
| — | BlackRock Funds III | 11.66% | — | $1.06B | — |
| VRTX | Vertex Pharmaceuticals, Inc.VRTX | 8.08% | $496.73 | $734.32M | 1.5M |
| AMGN | Amgen, Inc.AMGN | 7.83% | $362.12 | $711.36M | 2.0M |
| GILD | Gilead Sciences, Inc.GILD | 6.84% | $126.34 | $621.79M | 4.9M |
| REGN | Regeneron Pharmaceuticals, Inc.REGN | 4.91% | $623.54 | $445.87M | 715.1K |
| ARGX | Argenx SEARGX | 3.76% | $927.77 | $341.58M | 368.2K |
| ALNY | Alnylam Pharmaceuticals, Inc.ALNY | 3.12% | $301.03 | $283.62M | 942.2K |
| NTRA | Natera, Inc.NTRA | 2.89% | $271.45 | $262.68M | 967.7K |
| RVMD | Revolution Medicines, Inc.RVMD | 2.78% | $187.28 | $252.66M | 1.3M |
| BIIB | Biogen, Inc.BIIB | 2.47% | $216.06 | $224.09M | 1.0M |
Reported price is the fund's own reported value divided by its own reported shares at 2026-06-30 — not a live quote, and not what the fund paid.
Top 10 positions are 54.33% of net assets, top 25 75.43%, across 249 issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free